While varenicline (Chantix) has boasted quit rates higher than the nicotine patch in some prior studies, the drug has not been compared with a combination patch/lozenge strategy, which may offer unique benefits. In this 150-second analysis, MedPage Today medical reviewer F. Perry Wilson, MD, discusses a trial that finally pits these treatment strategies against each other.
, is an assistant professor of medicine at the Yale School of Medicine. He earned his BA from Harvard University, graduating with honors with a degree in biochemistry. He then attended Columbia College of Physicians and Surgeons in New York City. From there he moved to Philadelphia to complete his internal medicine residency and nephrology fellowship at the Hospital of the University of Pennsylvania. During his post graduate years, he also obtained a Master of Science in Clinical Epidemiology from the University of Pennsylvania. He is an accomplished author of many scientific articles and holds several NIH grants. He is a MedPage Today reviewer, and in addition to his video analyses, he authors a blog, . You can follow .